Innovus Pharma to Exhibit at 2017 American Society of Reproductive Medicine (“ASRM”) Scientific Congress and Expo in San Antonio, Texas

Dr. Fady I. Sharara, Head of the Company’s Clinical Advisory Board to Discuss Clinical Results Using Company’s Androferti® Products on Pregnancy Success Rate

SAN DIEGO--()--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it will exhibit at the American society of Reproductive Medicine (“ASRM”) Scientific Congress and Expo in San Antonio, Texas from Monday, October 30th to Wednesday, November 1st. Dr. Fady I. Sharara, who is the Head of the Company’s Clinical Advisory Board, will discuss current results and pregnancy success rates utilizing the Company’s Androferti® product.

Event: ASRM Scientific Congress and Expo

Dates: Monday, October 30, 2017 to Wednesday, November 1, 2017

Times: 9:00 am to 5:00 pm CST (Monday, October 30, 2017 and Tuesday, October 31, 2017) and 9:00 am to 2:00 pm CST on Wednesday, November 1, 2017.

Location: Henry B. Gonzalez Convention Center in San Antonio, Texas

About Dr. Sharara. Fady I. Sharara, M.D, FACOG is a Board Certified Reproductive Endocrinologist/Infertility specialist, and a Board-Certified Obstetrician/Gynecologist. He is the recipient of numerous prestigious awards, and has been consistently voted one of the Top Doctors in Infertility by the Washington Post magazine, Washingtonian magazine, and Northern Virginia magazine, among others. Dr. Sharara is a reviewer for Fertility and Sterility, Human Reproduction, the American Journal of Obstetrics and Gynecology, Human Fertility, Journal of Assisted Reproduction and Genetics. He has published more than 70 scientific papers and book chapters dealing with Infertility and Assisted Reproductive Technologies He received his B.S in Chemistry in 1982, and his M.D in 1986 from the American University of Beirut. He was on the Dean's honor list during his premedical and medical studies. He then completed his residency in OB/GYN at George Washington University Hospital in Washington, DC, USA, in 1991, followed by a fellowship in Reproductive Endocrinology and Infertility from 1991 to 1994 at the National Institutes of Health in Bethesda, MD. He moved to Chicago where he was an Assistant Professor at the University of Illinois and Michael Reese Fertility Center between 1994 and 1996. He then returned to the University of Maryland where he was Assistant Professor and head of the IVF program from 1996 to 2000. He was promoted to Associate Professor before his departure from the University of Maryland. Dr Sharara then became the founder and Medical Director for the Virginia Center for Reproductive Medicine (VCRM) in Reston, VA, and has been Clinical professor in the OB/GYN department at George Washington University in Washington, DC since 2007.

About Androferti®

Androferti is a unique, twice daily supplement with great orange flavor, clinically proven to improve sperm quality parameters – that is, concentration, motility, morphology and the capacity to fertilize the eggs. Unlike other supplements, Androferti®'s benefits have been proven in peer-reviewed clinical studies based on its unique formulation of L-carnitine with antioxidants, vitamins and minerals so it takes account of how they react with each other within the body, rather than making assumptions based on data for individual ingredients.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.urivarx.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.prostagorx.com; www.fluticare.com; www.allervarx.com; www.myandroferti.com and www.apeaz.com.

Innovus Pharma's Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the Androferti® product in the United States if approved in that country, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.

Contacts

Emerging Markets Consulting, LLC
James S. Painter III, 407 340 0226
jamespainter@emergingmarketsllc.com
or
Chesapeake Group
410-825-3930
info@chesapeakegp.com

Contacts

Emerging Markets Consulting, LLC
James S. Painter III, 407 340 0226
jamespainter@emergingmarketsllc.com
or
Chesapeake Group
410-825-3930
info@chesapeakegp.com